NTLA Deadline: NTLA Investors with Losses in Excess of $100K Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Intellia securities between July 30, 2024, and January 8, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 14, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360 [3]. Group 3: Case Background - The lawsuit alleges that Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, particularly about the timeline for dosing the first patient [4]. - It is claimed that Intellia failed to disclose the declining demand for viral-based editing methods, which could render NTLA-3001 an inefficient program [4].